Research Analysts’ Weekly Ratings Updates for Globus Medical (GMED)

Several analysts have recently updated their ratings and price targets for Globus Medical (NYSE: GMED):

• 7/28/2026 – Globus Medical is now covered by UBS Group AG. They set a “neutral” rating and a $82.00 price target on the stock.
• 7/28/2026 – Globus Medical is now covered by UBS Group AG. They set a “neutral” rating and a $82.00 price target on the stock.
• 7/16/2026 – Globus Medical had its price target lowered by Truist Financial Corporation from $115.00 to $100.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Globus Medical had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Globus Medical had its price target lowered by Royal Bank Of Canada from $120.00 to $115.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Globus Medical is now covered by BMO Capital Markets. They set an “outperform” rating and a $94.00 price target on the stock.
• 7/8/2026 – Globus Medical was upgraded by BMO Capital Markets to “strong-buy”.
• 7/8/2026 – Globus Medical had its price target lowered by Stifel Nicolaus from $95.00 to $80.00. They now have a “hold” rating on the stock.
• 7/6/2026 – Globus Medical was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/15/2026 – Globus Medical had its price target lowered by Piper Sandler from $115.00 to $100.00. They now have an “overweight” rating on the stock.
• 6/9/2026 – Globus Medical had its “overweight” rating reaffirmed by Piper Sandler.

Insiders Place Their Bets

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.38% of the company’s stock.

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.